Organisation paid for research Program year 2025 Source: CMS Open Payments

Aurora Rheumatology

Neither a doctor nor a teaching hospital

Research payments

$52,268

9 payments

Through program year 2025, Aurora Rheumatology is reported as receiving $52,268 in research payments, across 9 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$2,123	2
2024	Research	$30,159	2
2023	Research	$19,649	2
2022	Research	$150	1
2021	Research	$14	1
2020	Research	$173	1

Breakdown

Who paid Research payments · program years 2020–2025

E.R. Squibb & Sons, L.L.C. $52,081 7 payments
Novartis Pharmaceuticals Corporation $187 2 payments

Studies the money was for Research payments · program years 2020–2025

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) $28,349 2 payments
Phase III PsA #2 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rhe $19,047 2 payments
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na ve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF? Inhibitor Treatment $3,633 1 payment
Phase III SLE - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) $752 1 payment
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment $300 1 payment
A Randomized Partially Blinded Active Controlled Multicenter Study of Ecukinumab to Demonstrate Reduction of Radiographic Progression Versus Gp2017 Adalimumab Biosimilar at 104 Weeks and to Assess the Long Term Safety Tolerability and Efficacy Up to 2 Yea $173 1 payment
A Randomized Partially Blinded Active Controlled Multicenter Study of Ecukinumab to Demonstrate Reduction of Radiographic Progression Versus Gp2017 Adalimumab Biosimilar at 104 Weeks and to Assess the Long Term Safety Tolerability and Efficacy Up to 2 Years in Patients With Active Ankylosing Spondylitis $14 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.